Beck Bode LLC Takes $5.80 Million Position in Shockwave Medical, Inc. (NASDAQ:SWAV)

Beck Bode LLC acquired a new stake in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) during the fourth quarter, HoldingsChannel reports. The fund acquired 30,422 shares of the company’s stock, valued at approximately $5,797,000. Shockwave Medical accounts for approximately 1.3% of Beck Bode LLC’s holdings, making the stock its 26th largest holding.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lindbrook Capital LLC boosted its stake in Shockwave Medical by 64.8% in the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Shockwave Medical by 297.4% in the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after acquiring an additional 116 shares in the last quarter. Asset Management One Co. Ltd. acquired a new stake in Shockwave Medical in the fourth quarter valued at approximately $34,000. Operose Advisors LLC acquired a new stake in Shockwave Medical in the third quarter valued at approximately $49,000. Finally, Venturi Wealth Management LLC acquired a new stake in Shockwave Medical in the third quarter valued at approximately $82,000. 95.35% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Shockwave Medical

In other Shockwave Medical news, VP Trinh Phung sold 1,287 shares of Shockwave Medical stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $232.18, for a total value of $298,815.66. Following the completion of the transaction, the vice president now owns 32,933 shares of the company’s stock, valued at $7,646,383.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Isaac Zacharias sold 4,000 shares of Shockwave Medical stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $260.36, for a total value of $1,041,440.00. Following the sale, the insider now owns 61,372 shares in the company, valued at $15,978,813.92. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Trinh Phung sold 1,287 shares of Shockwave Medical stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $232.18, for a total transaction of $298,815.66. Following the completion of the sale, the vice president now owns 32,933 shares in the company, valued at approximately $7,646,383.94. The disclosure for this sale can be found here. Over the last quarter, insiders sold 89,813 shares of company stock valued at $22,863,919. Corporate insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SWAV shares. TheStreet upgraded shares of Shockwave Medical from a “c+” rating to a “b” rating in a research note on Thursday, February 15th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $335.00 price objective (up from $270.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Wolfe Research reiterated a “peer perform” rating on shares of Shockwave Medical in a research note on Friday, April 5th. CL King reiterated a “neutral” rating on shares of Shockwave Medical in a research note on Monday, April 8th. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $335.00 price objective (up from $263.00) on shares of Shockwave Medical in a research note on Friday, April 5th. Ten research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $309.11.

Shockwave Medical Stock Performance

Shares of Shockwave Medical stock traded up $0.68 during trading on Tuesday, hitting $330.19. 711,431 shares of the company’s stock were exchanged, compared to its average volume of 945,777. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.73 and a current ratio of 11.76. The business has a 50-day simple moving average of $296.22 and a 200-day simple moving average of $234.65. Shockwave Medical, Inc. has a 52-week low of $157.00 and a 52-week high of $331.58. The stock has a market capitalization of $12.35 billion, a price-to-earnings ratio of 85.32, a PEG ratio of 2.45 and a beta of 0.92.

Shockwave Medical (NASDAQ:SWAV) last released its quarterly earnings data on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The company had revenue of $202.98 million during the quarter, compared to analysts’ expectations of $199.43 million. During the same quarter in the previous year, the company earned $3.71 earnings per share. The firm’s revenue for the quarter was up 41.0% on a year-over-year basis. On average, research analysts forecast that Shockwave Medical, Inc. will post 4.94 EPS for the current year.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.